P-49 COVID 19-PANDEMIC AND OUTCOMES IN DECOMPENSATE CIRRHOSIS-10 MONTHS REVIEW
Background and Aims: Liver abnormalities are frequent in COVID-19 disease, AST and ALT abnormalities are present in about 60% of serious disease patients. However, liver insufficiency and liver mortality were not important concerns. Decompensate cirrhotic patients are a group of high risk for morbid...
Main Authors: | Priscila Pollo-Flores, Gabriel Alverca Meyas, Vanessa Rodrigues, Janaisa Moraes de Souza, Pamela Moura Rodrigues Cardoso, Iasmin Torres Leitão, Stephanie Cathren Fenizola dos Santos da Silva, Lívia Melo Villar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121001125 |
Similar Items
-
COVID-19 in decompensated cirrhosis
by: O. V. Tashchyan, et al.
Published: (2021-01-01) -
Improving Survival in Decompensated Cirrhosis
by: Amar Nath Mukerji, et al.
Published: (2012-01-01) -
Management options in decompensated cirrhosis
by: Shah NL, et al.
Published: (2015-07-01) -
Improving Survival in Patients with Decompensated Cirrhosis
by: Deepak Amarapurkar, et al.
Published: (2011-01-01) -
Predictors of 1-month and 3-months Hospital Readmissions in Decompensated Cirrhosis: A Prospective Study in a Large Asian Cohort
by: Ruchir Patel, et al.
Published: (2019-01-01)